BR112017015431A2 - composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto - Google Patents
composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um compostoInfo
- Publication number
- BR112017015431A2 BR112017015431A2 BR112017015431A BR112017015431A BR112017015431A2 BR 112017015431 A2 BR112017015431 A2 BR 112017015431A2 BR 112017015431 A BR112017015431 A BR 112017015431A BR 112017015431 A BR112017015431 A BR 112017015431A BR 112017015431 A2 BR112017015431 A2 BR 112017015431A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- thrombus formation
- compound
- blood thrombus
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000007536 Thrombosis Diseases 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 3
- 239000008280 blood Substances 0.000 title 3
- 210000004369 blood Anatomy 0.000 title 3
- 206010051055 Deep vein thrombosis Diseases 0.000 title 1
- 206010014522 Embolism venous Diseases 0.000 title 1
- 208000010378 Pulmonary Embolism Diseases 0.000 title 1
- 206010047249 Venous thrombosis Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000009424 thromboembolic effect Effects 0.000 title 1
- 208000004043 venous thromboembolism Diseases 0.000 title 1
- 108010080805 Factor XIa Proteins 0.000 abstract 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 201000005665 thrombophilia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105385P | 2015-01-20 | 2015-01-20 | |
| PCT/US2016/013507 WO2016118403A1 (en) | 2015-01-20 | 2016-01-15 | Factor xia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017015431A2 true BR112017015431A2 (pt) | 2018-01-16 |
Family
ID=56417605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015431A BR112017015431A2 (pt) | 2015-01-20 | 2016-01-15 | composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10123995B2 (enExample) |
| EP (1) | EP3247354B1 (enExample) |
| JP (1) | JP2018502137A (enExample) |
| KR (1) | KR20170103962A (enExample) |
| CN (1) | CN107106548A (enExample) |
| AU (1) | AU2016209623B2 (enExample) |
| BR (1) | BR112017015431A2 (enExample) |
| CA (1) | CA2973202A1 (enExample) |
| MX (1) | MX2017009445A (enExample) |
| RU (1) | RU2712268C2 (enExample) |
| WO (1) | WO2016118403A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9975874B2 (en) | 2014-07-28 | 2018-05-22 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| US10081617B2 (en) | 2015-04-16 | 2018-09-25 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| EP3383847B1 (en) * | 2015-12-02 | 2022-08-24 | Merck Sharp & Dohme LLC | FACTOR XIa INHIBITORS |
| WO2018039094A1 (en) | 2016-08-22 | 2018-03-01 | Merck Sharp & Dohme Corp. | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| JP6839208B2 (ja) * | 2016-10-12 | 2021-03-03 | 常州市派騰電子技術服務有限公司Ｃｈａｎｇｚｈｏｕ Ｐａｔｅｎｔ Ｅｌｅｃｔｒｏｎｉｃ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | 電子タバコの吸口、カートリッジ及び電子タバコ |
| CN113004286B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1966141A1 (en) * | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7829584B2 (en) * | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| JP5318094B2 (ja) * | 2007-06-13 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | 凝固因子阻害剤としてのジペプチド類似体 |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| US8828983B2 (en) * | 2010-02-11 | 2014-09-09 | Bristol-Myers Squibb Company | Macrocycles as factor XIa inhibitors |
| US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| KR20140052034A (ko) | 2011-08-19 | 2014-05-02 | 머크 샤프 앤드 돔 코포레이션 | 신장 외수질 칼륨 채널의 억제제 |
| US20150225404A1 (en) * | 2012-08-30 | 2015-08-13 | Nippon Shinyaku Co., Ltd. | Pyridine derivative and medicine |
| US9469608B2 (en) * | 2012-11-20 | 2016-10-18 | Merck Sharp & Dohme Corp. | Thrombin inhibitors |
| KR20170005871A (ko) * | 2014-05-28 | 2017-01-16 | 머크 샤프 앤드 돔 코포레이션 | 인자 XIa 억제제 |
| US9975874B2 (en) | 2014-07-28 | 2018-05-22 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| EP3180327B1 (en) | 2014-07-28 | 2019-05-08 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
-
2016
- 2016-01-15 US US15/542,948 patent/US10123995B2/en active Active
- 2016-01-15 RU RU2017129275A patent/RU2712268C2/ru not_active IP Right Cessation
- 2016-01-15 AU AU2016209623A patent/AU2016209623B2/en not_active Ceased
- 2016-01-15 JP JP2017537924A patent/JP2018502137A/ja not_active Ceased
- 2016-01-15 MX MX2017009445A patent/MX2017009445A/es unknown
- 2016-01-15 EP EP16740526.5A patent/EP3247354B1/en active Active
- 2016-01-15 CN CN201680006558.8A patent/CN107106548A/zh active Pending
- 2016-01-15 CA CA2973202A patent/CA2973202A1/en not_active Abandoned
- 2016-01-15 KR KR1020177022768A patent/KR20170103962A/ko not_active Withdrawn
- 2016-01-15 WO PCT/US2016/013507 patent/WO2016118403A1/en not_active Ceased
- 2016-01-15 BR BR112017015431A patent/BR112017015431A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20180000795A1 (en) | 2018-01-04 |
| EP3247354B1 (en) | 2019-08-07 |
| CN107106548A (zh) | 2017-08-29 |
| KR20170103962A (ko) | 2017-09-13 |
| RU2712268C2 (ru) | 2020-01-28 |
| EP3247354A4 (en) | 2018-06-27 |
| US10123995B2 (en) | 2018-11-13 |
| JP2018502137A (ja) | 2018-01-25 |
| MX2017009445A (es) | 2017-11-08 |
| RU2017129275A (ru) | 2019-02-21 |
| CA2973202A1 (en) | 2016-07-28 |
| WO2016118403A1 (en) | 2016-07-28 |
| EP3247354A1 (en) | 2017-11-29 |
| RU2017129275A3 (enExample) | 2019-07-26 |
| AU2016209623B2 (en) | 2019-11-14 |
| AU2016209623A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015431A2 (pt) | composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| EA033395B1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
| MX380901B (es) | Compuestos inhibidores de parg. | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
| TN2017000009A1 (en) | Spirocycloheptanes as inhibitors of rock. | |
| HK1220442A1 (zh) | Ido抑制剂 | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
| EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| HK1246164A1 (zh) | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| EA201990095A1 (ru) | КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| EA201791689A1 (ru) | Новые композиции и способы лечения и/или предупреждения хронического обструктивного заболевания легких |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |